Form 4: BridgeBio Pharma Director Acquires Stock Options

Director Randal W. Scott acquired stock options for 26,014 shares of BridgeBio Pharma, Inc. on June 21, 2024.

Summary

• Randal W. Scott, a director of BridgeBio Pharma, Inc., filed a Form 4 on June 25, 2024.
• The filing reports a transaction that occurred on June 21, 2024, where Scott acquired stock options for 26,014 shares.
• The exercise price of the stock options is $27.36.
• One-third of the shares underlying the stock option will vest each year after June 21, 2024, with full vesting on June 21, 2027, contingent upon continued service on the board.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.

Future Outlook

The stock options vest over a three-year period, contingent on the director's continued service, aligning the director's interests with the long-term performance of the company.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It reflects standard practices for incentivizing board members through equity-based compensation.

Stakeholder Impact

• The acquisition of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates